Mindwalk Holdings Corp (HYFT) Stock Price, Quote & News

Company Profile

MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock therapeutic possibilities. The company was formerly known as ImmunoPrecise Antibodies Ltd. and changed it...

Industry: Biotechnology

Sector: Healthcare

Phone: 800 620 4187

Website: www.mindwalkai.com

Address:

Industrious 823 Congress Ave, Suite 300, Austin, United States

NyseDayTrader Nov. 14 at 10:16 PM

$HYFT I want to start by saying that I 110% back this technology—and that's the reason for my large position in the company. Where I have a problem is with management, specifically Jennifer Bath. It demonstrates that the company lacks the innovative minds needed to keep pace with the groundbreaking technology it possesses. Instead of pioneering the next big drug, they seem to be chasing the hottest current trends in drug development. They did this with the COVID vaccine in 2021, and I'm certain it happened again with the standalone GLP-1 efforts, ultimately adding longevity to those pursuits. We have the technology, but we need more innovative minds in this company to truly unlock its potential.

0 · Reply

kozyman87 Nov. 14 at 9:13 PM

$HYFT https://x.com/mindwalkcorp/status/1989332652634116467?s=46&t=E5QDH-ldvkjpFG1z3szlLQ Our HYFT patterns are exact in finding sequences for new drugs. It's exactly what will work in this new age environment with higher and higher compute power availability's .......an exciting avenue for faster growth in discovery of new drugs and vaccines 🧬soon💸💰

1 · Reply

NyseDayTrader Nov. 14 at 3:05 PM

$HYFT Did we invest in a educational company or a get shit done company! bath might be the highest payed educator in the history of the world

1 · Reply

NyseDayTrader Nov. 14 at 2:06 PM

$HYFT https://x.com/mindwalkcorp/status/1989332652634116467/video/1

0 · Reply

Gtrading1234 Nov. 14 at 4:12 AM

$HYFT

0 · Reply

Thehardtruth Nov. 13 at 11:13 PM

$HYFT what the hell happened today?

1 · Reply

Prazzclatt Nov. 13 at 9:04 PM

$HYFT AI drug discovery is the new frontier waiting to get established, as soon as it becomes even a bit more mainstream this will skyrocket

0 · Reply

NyseDayTrader Nov. 13 at 2:07 PM

$HYFT AUSTIN, Texas--(BUSINESS WIRE)-- MindWalk Holdings Corp.™ (“MindWalk,” “Company,” “we” or “us”) (Nasdaq: HYFT), a Bio-Native AI company, today announced that Dr. Dirk Van Hyfte, Chief Technology Officer, will participate in a fireside chat during the Biology Session at the AI Drug Discovery & Development Summit 2025, taking place on November 20, 2025, from 12:15 PM to 12:45 PM. The AI Drug Discovery & Development Summit is a premier event that brings together industry leaders, researchers, and innovators to explore how artificial intelligence is reshaping drug discovery pipelines and accelerating therapeutic development. Dr. Van Hyfte will share insights on how MindWalk’s HYFT®-powered LensAi™ platform is unlocking new opportunities to index, connect, and continuously update biological knowledge at scale—redefining how the industry approaches discovery and development. “We’re pleased to see Dr. Van Hyfte representing MindWalk’s vision for Bio-Native AI and Deep Data internationally,” said Dr. Jennifer Bath, CEO of MindWalk. “His work exemplifies how scientific depth and data-driven design can come together to advance precision discovery.” For more information on the event, visit the official website: AI Drug Discovery & Development Summit 2025

0 · Reply

NyseDayTrader Nov. 13 at 12:56 AM

$HYFT the calm before the storm? Smart accumulation occurring here

0 · Reply

Risk1123 Nov. 12 at 9:13 PM

$HYFT how we feel lads

0 · Reply

MindWalk CTO Dr. Dirk Van Hyfte to Join Fireside Chat at AI Drug Discovery & Development Summit 2025

Oct 21, 2025, 8:28 AM EDT - 24 days ago

MindWalk Appoints R. Scott Areglado as Chief Financial Officer to Strengthen Financial Leadership and Support Growth Strategy

Oct 17, 2025, 8:18 AM EDT - 4 weeks ago

MindWalk Holdings: Repositioned TechBio Platform With Early LensAI Proof Points

Oct 15, 2025, 7:00 AM EDT - 4 weeks ago

MindWalk Appoints Dr. Thomas W. Lynch as Chief Business Officer to Accelerate Commercial Expansion

Oct 9, 2025, 2:26 PM EDT - 5 weeks ago

MindWalk Holdings Corp. (HYFT) ImmunoPrecise Antibodies Ltd. - Shareholder/Analyst Call Prepared Remarks Transcript

Oct 9, 2025, 7:00 AM EDT - 5 weeks ago

MindWalk Announces Share Repurchase Program

Sep 22, 2025, 7:02 AM EDT - 7 weeks ago

MindWalk Advances AI-Designed GLP-1 Program with First-in-Class Dual-Pathway Regimen for Aging and Longevity

Sep 15, 2025, 12:58 PM EDT - 2 months ago

MindWalk Holdings Corp. (HYFT) Q1 2026 Earnings Call Transcript

Sep 15, 2025, 8:44 AM EDT - 2 months ago

MindWalk Holdings Corp.™ (formerly ImmunoPrecise Antibodies™) Reports Record $7.6 Million Quarterly Revenue, 45% Growth, Margin Expansion, Narrowed Losses, and Strengthened Balance Sheet

Sep 3, 2025, 8:48 AM EDT - 2 months ago

ImmunoPrecise Rebrands as MindWalk, Announces NASDAQ Ticker Change to “HYFT”

Sep 2, 2025, 8:01 AM EDT - 2 months ago

ImmunoPrecise Antibodies to Participate at H.C. Wainwright's 27th Annual Global Investment Conference in New York

Aug 27, 2025, 8:22 AM EDT - 2 months ago

ImmunoPrecise Advances AI Discovered and Developed Universal Dengue Vaccine Initiative: Moves into Preclinical Antibody Generation

Aug 6, 2025, 8:00 AM EDT - 3 months ago

ImmunoPrecise Antibodies Ltd. Divests Netherlands Facilities to AVS Bio to Accelerate Bio-Native AI Innovation

Aug 6, 2025, 8:00 AM EDT - 3 months ago

AVS Bio, an Arlington Capital Partners Portfolio Company, Expands Antibody Discovery and Protein Production Capabilities With Acquisition of ImmunoPrecise Antibodies Europe From ImmunoPrecise Antibodies Ltd.

Jul 29, 2025, 12:39 PM EDT - 3 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q4 2025 Earnings Conference Call Transcript

Jul 29, 2025, 8:28 AM EDT - 3 months ago

ImmunoPrecise Antibodies (IPA) Reports Full Fiscal Year 2025 Results, Record Fourth Quarter Revenue, and Record Fourth Quarter Adjusted EBITDA

Jul 24, 2025, 8:22 AM EDT - 4 months ago

ImmunoPrecise Releases New Findings Showing LENSai™ Quickly Flags Anti-Drug-Antibody Risk—Long Before the Clinic

Jul 21, 2025, 8:28 AM EDT - 4 months ago

ImmunoPrecise Appoints Healthcare Data Visionary Jeff Fried to Advisory Board

Jul 16, 2025, 8:05 AM EDT - 4 months ago

IPA to Report Financial Results and Recent Business Highlights for Fourth Quarter and Full Fiscal Year 2025 on July 29, 2025

Jul 14, 2025, 8:01 AM EDT - 4 months ago

ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement

Jul 7, 2025, 9:00 AM EDT - 4 months ago

ImmunoPrecise Antibodies Appoints Industry Veteran Jon Lieber to Board of Directors

Jul 3, 2025, 8:19 AM EDT - 4 months ago

ImmunoPrecise Validates LENSai Epitope Mapping Platform Across Broad Range of Unseen Therapeutic Targets Beyond Training Data

Jun 24, 2025, 7:02 AM EDT - 5 months ago

ImmunoPrecise Advances Universal Dengue Vaccine, Confirming Safety, Immune Activation, and Structural Stability Using its LENSai™ Platform Powered by Patented HYFT® Technology

Jun 12, 2025, 8:01 AM EDT - 5 months ago

AI-Designed GLP-1 Peptides from ImmunoPrecise Antibodies Surpass Semaglutide in Receptor Activation Studies

Jun 5, 2025, 8:01 AM EDT - 5 months ago

ImmunoPrecise Announces AI-Driven Breakthrough in Universal Dengue Vaccine Discovery

AMD

May 21, 2025, 8:49 AM EDT - 6 months ago

ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts

May 20, 2025, 8:28 AM EDT - 6 months ago

ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference

May 12, 2025, 8:01 AM EDT - 6 months ago

IPA's LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed

AMD

Apr 11, 2025, 8:40 AM EDT - 7 months ago

ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods

Mar 28, 2025, 12:59 PM EDT - 8 months ago

ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript

Mar 28, 2025, 8:01 AM EDT - 8 months ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025

Mar 13, 2025, 7:02 AM EDT - 8 months ago

ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics.

Mar 11, 2025, 10:17 PM EDT - 8 months ago

IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025

Mar 5, 2025, 8:01 AM EST - 9 months ago

IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025

Feb 26, 2025, 8:01 AM EST - 9 months ago

IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy

Feb 24, 2025, 8:01 AM EST - 9 months ago

ImmunoPrecise Antibodies Announces Key Leadership Changes

Feb 20, 2025, 8:01 AM EST - 9 months ago

ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period

Jan 27, 2025, 8:01 AM EST - 10 months ago

ImmunoPrecise Antibodies (IPA) Announces Completion of At-the-Market Equity Offering and Full Conversion of Yorkville Debenture

Jan 22, 2025, 7:02 AM EST - 10 months ago

IPA (ImmunoPrecise Antibodies) Pioneers AI-Designed GLP-1 Therapies: A Potential New Chapter in Diabetes Treatment

Jan 17, 2025, 8:01 AM EST - 10 months ago

ImmunoPrecise Antibodies Realigns Pipeline Strategy, Empowering Drug Discovery with AI and First-Principles Innovation

Dec 31, 2024, 7:56 PM EST - 11 months ago

IPA Announces Resignation of Chief Financial Officer

Dec 30, 2024, 10:03 PM EST - 11 months ago

$116 Million Multifamily Asset Sale in Central California Coast Region Brokered by Marcus & Millichap's Institutional Property Advisors

MMI

Dec 23, 2024, 8:30 AM EST - 11 months ago

ImmunoPrecise Antibodies (IPA) Demonstrates Strong Market Confidence with Insider Share Purchases

Dec 19, 2024, 10:15 AM EST - 11 months ago

IPA to Present at The Microcap Conference 2025

Dec 10, 2024, 5:33 PM EST - 1 year ago

ImmunoPrecise Antibodies Ltd. (IPA) Q2 2025 Earnings Call Transcript

Dec 10, 2024, 8:30 AM EST - 1 year ago

ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025

Dec 4, 2024, 8:00 AM EST - 1 year ago

IPA to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

Dec 3, 2024, 8:30 AM EST - 1 year ago

IPA to Report Financial Results and Recent Business Highlights for Second Quarter Fiscal Year 2025 on December 10, 2024

Nov 13, 2024, 9:00 AM EST - 1 year ago

$20 Billion Market Breakthrough: IPA Pioneers High-Impact Antibody Development for Next-Generation ADC Cancer Therapies

Nov 4, 2024, 8:01 AM EST - 1 year ago

ImmunoPrecise to Host TECHDAY: Cutting-Edge AI and Biologics Innovation

NyseDayTrader Nov. 14 at 10:16 PM

0 · Reply

kozyman87 Nov. 14 at 9:13 PM

1 · Reply

NyseDayTrader Nov. 14 at 3:05 PM

$HYFT Did we invest in a educational company or a get shit done company! bath might be the highest payed educator in the history of the world

1 · Reply

NyseDayTrader Nov. 14 at 2:06 PM

$HYFT https://x.com/mindwalkcorp/status/1989332652634116467/video/1

0 · Reply

Gtrading1234 Nov. 14 at 4:12 AM

$HYFT

0 · Reply

Thehardtruth Nov. 13 at 11:13 PM

$HYFT what the hell happened today?

1 · Reply

Prazzclatt Nov. 13 at 9:04 PM

$HYFT AI drug discovery is the new frontier waiting to get established, as soon as it becomes even a bit more mainstream this will skyrocket

0 · Reply

NyseDayTrader Nov. 13 at 2:07 PM

0 · Reply

NyseDayTrader Nov. 13 at 12:56 AM

$HYFT the calm before the storm? Smart accumulation occurring here

0 · Reply

Risk1123 Nov. 12 at 9:13 PM

$HYFT how we feel lads

0 · Reply

DiamondHandsHarold Nov. 12 at 6:03 PM

$HYFT is using AI to speed up drug discovery. Feels like a quiet one that could surprise people.

0 · Reply

NyseDayTrader Nov. 12 at 2:21 PM

$HYFT

1 · Reply

Magnificent77 Nov. 11 at 10:17 PM

$HYFT wait until JNJ or one of those big names starts using AI drug discovery and finds out these guys are at the forefront of it all

1 · Reply

diamonhands72 Nov. 11 at 9:35 PM

$HYFT AI in drug discovery will find things that Humans can't!

0 · Reply

Tunes444 Nov. 11 at 9:26 PM

$HYFT

0 · Reply

NyseDayTrader Nov. 11 at 11:14 AM

$HYFT just read this headline on X. BREAKING: Chinese scientists are developing a drug to extend human life to 150 years. Giddy up Bath

1 · Reply

Thehardtruth Nov. 11 at 12:26 AM

$HYFT this stock actually feels strong to me. but very long term hold

1 · Reply

NyseDayTrader Nov. 10 at 4:16 PM

$HYFT trading so far is a validation that this is a smart finance deal and not a desperate dilutive event

0 · Reply

NyseDayTrader Nov. 10 at 2:55 PM

$HYFT

0 · Reply

NyseDayTrader Nov. 10 at 1:10 PM

$HYFT From X board Trump's obesity drug price cuts + patent cliffs are pushing pharmaceutical companies to strain themselves and acquire companies holding those pipelines, just like in the text below. This is the best situation for MindWalk. MindWalk $HYFT's GLP-1 treatment is currently in the In vivo "preclinical design" stage, before submitting for clinical trials. Key points to watch: 1) Out of a total of 5 GLP-1 candidates designed with the LensAI platform, 2 showed activity levels that are stronger or equivalent to the semaglutide in existing Ozempic and Wegovy. => This means molecules designed with AI are comparable to or more effective than existing treatments. => However, whether they actually work in humans must be proven in clinical trials. 2) The fact that they're expanding experiments in the In Vivo stage of these existing GLP-1 candidates and pursuing longevity treatments in parallel as well. => The current GLP-1-based drugs are a blue ocean. => The world's first GLP-1 for anti-aging treatment made with AI (from the company's perspective). => A $60 billion longevity market. => As can be seen from the leaked conversation between Xi Jinping & Putin, demand from the power elite is on the rise. Once they submit the IND for clinical trials, MindWalk will look for a partner to conduct the trials on their behalf—what do you think the ending of this story will be?

0 · Reply

Suckhood Nov. 8 at 8:28 PM

$HYFT i love this stock i bought it for.40 cents when was ipa i thought it was a beer find a glp 1 you can put in beer go jen go

0 · Reply

NyseDayTrader Nov. 8 at 3:59 PM

$HYFT my guess is they’re going to use the repurchase program to support the stock when skittish shareholders sell Monday. In turn raising money at $1.70+

0 · Reply

Market Cap	82.62M
Revenue (ttm)	17.59M
Net Income (ttm)	-21.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-123.31%
Debt to Equity Ratio	0.00

Volume	260,900
Avg Vol	915,878
Day's Range	N/A - N/A
Shares Out	46.16M
Stochastic %K	61%
Beta	0.48
Analysts	Sell
Price Target	$4.00